{"id":"NCT03211858","sponsor":"Sanofi","briefTitle":"Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine","officialTitle":"Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog®/NovoRapid® in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine, With a 6-month Safety Extension Period","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-02","primaryCompletion":"2018-07-16","completion":"2019-01-12","firstPosted":"2017-07-07","resultsPosted":"2019-08-08","lastUpdate":"2022-03-28"},"enrollment":597,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Insulin aspart","otherNames":[]},{"type":"DRUG","name":"NovoLog/NovoRapid","otherNames":["Insulin aspart"]},{"type":"DRUG","name":"Insulin glargine (HOE901)","otherNames":["Lantus"]}],"arms":[{"label":"SAR341402","type":"EXPERIMENTAL"},{"label":"NovoLog/NovoRapid","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\nTo demonstrate non-inferiority of SAR341402 versus NovoLog/NovoRapid in glycated hemoglobin A1c (HbA1c) change from baseline to Week 26 in participants with type 1 or type 2 diabetes mellitus (T1DM or T2DM) also using Lantus®.\n\nSecondary Objectives:\n\n* To assess the immunogenicity of SAR341402 and NovoLog/NovoRapid in terms of positive/negative status and anti-insulin antibody (AIA) titers during the course of the study.\n* To assess the relationship of AIAs with efficacy and safety.\n* To assess the efficacy of SAR341402 and NovoLog/NovoRapid in terms of proportion of participants reaching HbA1c lesser than (\\<) 7.0% and change in HbA1c, fasting plasma glucose (FPG), and self-measured plasma glucose (SMPG) profiles from baseline to Week 26 and Week 52 (only Week 52 for HbA1c).\n* To assess safety of SAR341402 and NovoLog/NovoRapid.","primaryOutcome":{"measure":"Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26","timeFrame":"Baseline, Week 26","effectByArm":[{"arm":"SAR341402","deltaMin":-0.38,"sd":0.042},{"arm":"NovoLog/NovoRapid","deltaMin":-0.3,"sd":0.041}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":16},"locations":{"siteCount":82,"countries":["United States","Finland","Germany","Hungary","Japan","Poland","Russia"]},"refs":{"pmids":["31804851","32068436","33432547"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":301},"commonTop":["Nasopharyngitis","Upper Respiratory Tract Infection","Influenza"]}}